Nothing Special   »   [go: up one dir, main page]

CR20150077A - ORAL PHARMACEUTICAL COMPOSITION IN THE FORM OF MICROSPHERES AND ELABORATION PROCESS - Google Patents

ORAL PHARMACEUTICAL COMPOSITION IN THE FORM OF MICROSPHERES AND ELABORATION PROCESS

Info

Publication number
CR20150077A
CR20150077A CR20150077A CR20150077A CR20150077A CR 20150077 A CR20150077 A CR 20150077A CR 20150077 A CR20150077 A CR 20150077A CR 20150077 A CR20150077 A CR 20150077A CR 20150077 A CR20150077 A CR 20150077A
Authority
CR
Costa Rica
Prior art keywords
microspheres
pharmaceutical composition
oral pharmaceutical
elaboration process
elaboration
Prior art date
Application number
CR20150077A
Other languages
Spanish (es)
Inventor
Hernández Gustavo Barranco
Guiza María Del Coral Luna
Arroyo Héctor Senosiain
Original Assignee
Senosiain S A De C V Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=50435594&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CR20150077(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Senosiain S A De C V Lab filed Critical Senosiain S A De C V Lab
Publication of CR20150077A publication Critical patent/CR20150077A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/167—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/549—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame having two or more nitrogen atoms in the same ring, e.g. hydrochlorothiazide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Endocrinology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Una composición en forma de micropartículas que constanprincipalmente de: a) un núcleo inerte; b) una capa deprincipio activo formada por aspersión sobre el núcleoinerte y c) opcionalmente un segundo recubrimiento quecomprende una o más capas de fármaco(s) y/o excipiente(s)farmacéuticamente aceptable(s).A composition in the form of microparticles consisting primarily of: a) an inert nucleus; b) an active principle layer formed by spraying on the core and c) optionally a second coating comprising one or more layers of pharmaceutically acceptable drug (s) and / or excipient (s).

CR20150077A 2012-08-17 2015-02-13 ORAL PHARMACEUTICAL COMPOSITION IN THE FORM OF MICROSPHERES AND ELABORATION PROCESS CR20150077A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
MX2012009583A MX351059B (en) 2012-08-17 2012-08-17 Oral pharmaceutical composition in the form of microspheres and preparation method.
PCT/IB2013/056690 WO2014027334A2 (en) 2012-08-17 2013-08-16 Oral pharmaceutical composition in the form of microspheres and preparation method

Publications (1)

Publication Number Publication Date
CR20150077A true CR20150077A (en) 2015-05-13

Family

ID=50435594

Family Applications (1)

Application Number Title Priority Date Filing Date
CR20150077A CR20150077A (en) 2012-08-17 2015-02-13 ORAL PHARMACEUTICAL COMPOSITION IN THE FORM OF MICROSPHERES AND ELABORATION PROCESS

Country Status (8)

Country Link
CL (1) CL2015000375A1 (en)
CO (1) CO7310526A2 (en)
CR (1) CR20150077A (en)
DO (1) DOP2015000028A (en)
GT (1) GT201500035A (en)
MX (1) MX351059B (en)
PE (1) PE20150710A1 (en)
WO (1) WO2014027334A2 (en)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUE039973T2 (en) 2013-03-27 2019-02-28 Hoffmann La Roche Genetic markers for predicting responsiveness to therapy
RU2703192C2 (en) 2014-07-30 2019-10-15 Ф. Хоффманн-Ля Рош Аг Genetic markers for predicting response to therapy by raising hdl level or imitating hdl agents
CN104523710B (en) * 2014-12-30 2018-05-25 石药集团欧意药业有限公司 A kind of bisulfate clopidogrel aspirin Composite Double synusia and preparation method thereof
KR101710441B1 (en) * 2015-12-28 2017-02-28 신풍제약주식회사 Tablet with improved stability and dissolution
WO2018150286A1 (en) 2017-02-17 2018-08-23 Unichem Laboratories Ltd Pharmaceutical composition of apixaban
CN106821996A (en) * 2017-03-01 2017-06-13 华益药业科技(安徽)有限公司 Enalapril maleate granule and preparation method thereof
HRP20240529T1 (en) * 2018-04-16 2024-07-05 Bristol-Myers Squibb Company Apixaban formulations
WO2021168043A1 (en) * 2020-02-19 2021-08-26 Nano Pharmasolutions, Inc. Therapeutic agent nanoparticles and methods of preparation
US11833133B2 (en) * 2020-08-13 2023-12-05 Orient Pharma Co., Ltd. Solid oral pharmaceutical composition
CN113413364A (en) * 2021-05-31 2021-09-21 辰欣药业股份有限公司 Enoxaparin sodium injection and preparation method thereof

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2007208998A1 (en) * 2006-01-27 2007-08-02 The Provost, Fellows And Scholars Of The College Of The Holy And Undivided Trinity Of Queen Elizabeth Near Dublin A method of producing porous microparticles
MXPA06010972A (en) * 2006-09-25 2009-04-17 World Trade Imp Export Wtie Ag Process for stabilizing famotidine.
WO2008045006A1 (en) * 2006-10-11 2008-04-17 Fako Ilaclari A. S. Formulations of candesartan
MX2007008440A (en) * 2007-07-11 2009-02-18 Senosiain S A De C V Lab Combined pharmaceutical composition.

Also Published As

Publication number Publication date
PE20150710A1 (en) 2015-05-28
CL2015000375A1 (en) 2015-07-10
CO7310526A2 (en) 2015-06-30
GT201500035A (en) 2017-10-24
DOP2015000028A (en) 2015-03-15
MX2012009583A (en) 2014-02-26
MX351059B (en) 2017-09-29
WO2014027334A2 (en) 2014-02-20
WO2014027334A3 (en) 2014-04-10

Similar Documents

Publication Publication Date Title
CR20150077A (en) ORAL PHARMACEUTICAL COMPOSITION IN THE FORM OF MICROSPHERES AND ELABORATION PROCESS
CY1120783T1 (en) DURABLE AGAINST VIOLATION AND RESISTANT AGAINST DOSAGE SHIPPING PHARMACEUTICAL DOSAGE
CL2013000424A1 (en) Break-resistant pharmaceutical dosage form comprising a) a pharmacologically active ingredient, b) a polymer, c) a polyalkylene oxide, where a) is present in a controlled release matrix comprising b) and c).
CL2014002754A1 (en) Solid controlled release dose form comprising a nucleus with a first portion of an opioid analgesic and a cover that encloses the nucleus and comprises a second portion of the opioid analgesic; Preparation method; use in the treatment of pain. (divisional of application n ° 1450-2014).
CL2013002504A1 (en) Solid coated pharmaceutical preparation comprising at least one active ingredient and because the coating has a thickness of 0.1 to 100 nm, preferably 0.3 to 50 nm and more preferably 0.5 to 35 nm; and its method of preparation
FI20145771L (en) Parasiticidal oral veterinary drug compositions comprising systemically acting active agents, methods and uses thereof
AR096439A1 (en) DOSAGE METHOD RESISTING TO INDEED USE CONTAINING ONE OR MORE PARTICLES
BR112014012005A2 (en) compositions, methods, pharmaceutical formulation and article
CR20140487A (en) MULTIPLE LAYER FILMS ABLE TO RELEASE ACTIVE INGREDIENTS FOR A LIMITED TIME PERIOD
CL2014000904A1 (en) Rupture-resistant oral pharmaceutical dosage form comprising i) a pharmacologically active ingredient, ii) an opioid antagonist and / or a repellent agent, iii) a polyalkylene oxide and iv) an anionic polymer.
CL2014001016A1 (en) Condensed tricyclic compounds and their pharmaceutically acceptable salts; pharmaceutical composition that includes them; and its use in the treatment of a viral infection.
CL2013003650A1 (en) Composition for the treatment of a staphylococcus aureus infection that contains only a luke anti leucocidin antibody and a pharmaceutically acceptable carrier.
BR112013030472A2 (en) pharmaceutical formulation, article of manufacture and method
DOP2016000024A (en) PHARMACEUTICAL COMPRESSED UNDERSTANDING ACETILSALICYL ACID AND CLOPIDOGREL
WO2011140446A3 (en) Pharmaceutical formulations
CL2013003229A1 (en) Hepatitis C virus (vhc) inhibitor compounds; pharmaceutical composition that includes them; and use in the treatment of a vhc infection.
CO2017006898A2 (en) Insulin glargine / lixisenatide fixed ratio formulation
EP3481381A4 (en) Oral dosage form with drug composition, barrier layer and drug layer
CR20140540A (en) NEW DOSAGE FORM AND FORMULATION OF ABEDITEROL
CL2014002988A1 (en) Method of manufacturing a pharmaceutical dosage form comprising nifedipine and candesartan cilexetil.
CL2013003700A1 (en) Topical ophthalmological pharmaceutical composition comprising regorafenib, which is suspended in a pharmaceutically acceptable vehicle; manufacturing procedure and its use to treat or prevent an ophthalmological disorder.
CL2014002896A1 (en) A pharmaceutical formulation in the form of a coated tablet consisting of a) a nucleus obtained from a co-mixture of mannitol, croscarmellose sodium and at least one active compound, and b) a coating which is applied in the form of an aqueous solution or one containing water and alcohol, and where the tablet disintegrates rapidly in the presence of moisture; and its preparation process.
AR092356A1 (en) COMPOSITE FORMULATION FOR ORAL ADMINISTRATION THAT INCLUDES METFORMIN AND ROSUVASTATIN AND METHOD OF PREPARATION OF THE FORMULATION
GT201400042A (en) BENZOTIAZOLONA COMPOSITE
PH12016500693B1 (en) Slow-release solid oral compositions